The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans

Antimicrob Agents Chemother. 2015 Jan;59(1):690-2. doi: 10.1128/AAC.03944-14. Epub 2014 Oct 20.

Abstract

The in vitro and in vivo activity of the inositol acyltransferase inhibitor E1210 was evaluated against echinocandin-resistant Candida albicans. E1210 demonstrated potent in vitro activity, and in mice with invasive candidiasis caused by echinocandin-resistant C. albicans, oral doses of 10 and 40 mg E1210/kg of body weight twice daily significantly improved survival and reduced fungal burden compared to those of controls and mice treated with caspofungin (10 mg/kg/day). These results demonstrate the potential use of E1210 against resistant C. albicans infections.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aminopyridines / pharmacology*
  • Aminopyridines / therapeutic use
  • Animals
  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use
  • Candida albicans / drug effects*
  • Candidiasis, Invasive / drug therapy*
  • Caspofungin
  • Dose-Response Relationship, Drug
  • Drug Resistance, Fungal
  • Echinocandins / pharmacology
  • Echinocandins / therapeutic use
  • Fluconazole / pharmacology
  • Fluconazole / therapeutic use
  • Isoxazoles / pharmacology*
  • Isoxazoles / therapeutic use
  • Lipopeptides
  • Male
  • Mice
  • Mice, Inbred ICR
  • Microbial Sensitivity Tests

Substances

  • APX001A
  • Aminopyridines
  • Antifungal Agents
  • Echinocandins
  • Isoxazoles
  • Lipopeptides
  • Fluconazole
  • Caspofungin